| Quarter | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|
| 0 | 13 | 19 | 39 | 44 | 46 | 55 | |
Growth YoY Revenue Growth YoY% | 190.7 | 135.7 | 18.2 | 25.8 | |||
| 0 | 11 | 14 | 31 | 37 | 38 | 43 | |
| 0 | 3 | 4 | 8 | 7 | 8 | 12 | |
OPM OPM% | 19.2 | 23.4 | 19.4 | 16.2 | 17.2 | 22.2 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Interest Expense Interest ExpenseCr | 0 | 0 | 1 | 1 | 0 | 0 | 1 |
Depreciation DepreciationCr | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
PBT PBTCr | 0 | 2 | 4 | 7 | 7 | 7 | 12 |
| 0 | 1 | 1 | 2 | 2 | 2 | 3 | |
| 0 | 1 | 2 | 4 | 5 | 5 | 8 | |
Growth YoY PAT Growth YoY% | 190.6 | 93.1 | 13.6 | 72.6 | |||
NPM NPM% | 11.2 | 13.3 | 11.2 | 10.9 | 10.7 | 14.9 | |
| 0.0 | 2.0 | 3.1 | 5.3 | 4.6 | 4.4 | 7.4 |
| Quarter | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|
| 0 | 13 | 19 | 39 | 44 | 46 | 55 | |
Growth YoY Revenue Growth YoY% | 190.7 | 135.7 | 18.2 | 25.8 | |||
| 0 | 11 | 14 | 31 | 37 | 38 | 43 | |
| 0 | 3 | 4 | 8 | 7 | 8 | 12 | |
OPM OPM% | 19.2 | 23.4 | 19.4 | 16.2 | 17.2 | 22.2 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Interest Expense Interest ExpenseCr | 0 | 0 | 1 | 1 | 0 | 0 | 1 |
Depreciation DepreciationCr | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
PBT PBTCr | 0 | 2 | 4 | 7 | 7 | 7 | 12 |
| 0 | 1 | 1 | 2 | 2 | 2 | 3 | |
| 0 | 1 | 2 | 4 | 5 | 5 | 8 | |
Growth YoY PAT Growth YoY% | 190.6 | 93.1 | 13.6 | 72.6 | |||
NPM NPM% | 11.2 | 13.3 | 11.2 | 10.9 | 10.7 | 14.9 | |
| 0.0 | 2.0 | 3.1 | 5.3 | 4.6 | 4.4 | 7.4 |
| Financial Year | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|
Revenue RevenueCr | 22 | 29 | 13 | 57 | 90 | 101 |
Growth Revenue Growth% | 31.8 | -54.5 | 329.7 | 56.2 | 22.3 | |
| 21 | 27 | 11 | 46 | 75 | 81 | |
| 2 | 2 | 3 | 12 | 15 | 20 | |
OPM OPM% | 7.4 | 6.7 | 19.2 | 20.7 | 16.7 | 19.9 |
| 0 | 0 | 0 | 0 | |||
Interest Expense Interest ExpenseCr | 1 | 1 | 0 | 1 | 1 | 1 |
Depreciation DepreciationCr | 1 | 1 | 0 | 1 | 1 | 2 |
PBT PBTCr | 0 | 0 | 2 | 10 | 13 | 19 |
| 0 | 0 | 1 | 3 | 3 | 4 | |
PAT PATCr | 0 | 0 | 1 | 7 | 10 | 13 |
Growth PAT Growth% | 25.0 | 1,392.8 | 355.1 | 42.3 | 44.5 | |
NPM NPM% | 0.4 | 0.3 | 11.2 | 11.8 | 10.8 | 13.0 |
| 2.0 | 8.5 | 9.0 | 11.8 |
| Financial Year | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|
Revenue RevenueCr | 22 | 29 | 13 | 57 | 90 | 101 |
Growth Revenue Growth% | 31.8 | -54.5 | 329.7 | 56.2 | 22.3 | |
| 21 | 27 | 11 | 46 | 75 | 81 | |
| 2 | 2 | 3 | 12 | 15 | 20 | |
OPM OPM% | 7.4 | 6.7 | 19.2 | 20.7 | 16.7 | 19.9 |
| 0 | 0 | 0 | 0 | |||
Interest Expense Interest ExpenseCr | 1 | 1 | 0 | 1 | 1 | 1 |
Depreciation DepreciationCr | 1 | 1 | 0 | 1 | 1 | 2 |
PBT PBTCr | 0 | 0 | 2 | 10 | 13 | 19 |
| 0 | 0 | 1 | 3 | 3 | 4 | |
PAT PATCr | 0 | 0 | 1 | 7 | 10 | 13 |
Growth PAT Growth% | 25.0 | 1,392.8 | 355.1 | 42.3 | 44.5 | |
NPM NPM% | 0.4 | 0.3 | 11.2 | 11.8 | 10.8 | 13.0 |
| 2.0 | 8.5 | 9.0 | 11.8 |
| Financial Year | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|---|
Equity Capital Equity CapitalCr | 4 | 8 | 11 | 11 |
Reserves ReservesCr | 1 | 7 | 44 | 52 |
| 15 | 23 | 21 | ||
| 7 | 1 | 1 | ||
| 27 | 40 | 77 | 87 | |
| 22 | 33 | 60 | ||
| 5 | 6 | 16 | ||
| 27 | 40 | 77 | 87 |
| Financial Year | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|---|
Equity Capital Equity CapitalCr | 4 | 8 | 11 | 11 |
Reserves ReservesCr | 1 | 7 | 44 | 52 |
| 15 | 23 | 21 | ||
| 7 | 1 | 1 | ||
| 27 | 40 | 77 | 87 | |
| 22 | 33 | 60 | ||
| 5 | 6 | 16 | ||
| 27 | 40 | 77 | 87 |
| Financial Year | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| -12 | -1 | -15 | |
| -5 | -2 | -9 | |
| 17 | 2 | 27 | |
Net Cash Flow Net Cash FlowCr | 0 | 0 | 4 |
Free Cash Flow Free Cash FlowCr | -17 | -2 | -23 |
CFO To PAT CFO To PAT% | -771.0 | -9.1 | -150.3 |
CFO To EBITDA CFO To EBITDA% | -449.0 | -5.2 | -97.1 |
| Financial Year | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| -12 | -1 | -15 | |
| -5 | -2 | -9 | |
| 17 | 2 | 27 | |
Net Cash Flow Net Cash FlowCr | 0 | 0 | 4 |
Free Cash Flow Free Cash FlowCr | -17 | -2 | -23 |
CFO To PAT CFO To PAT% | -771.0 | -9.1 | -150.3 |
CFO To EBITDA CFO To EBITDA% | -449.0 | -5.2 | -97.1 |
| Financial Year | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Current |
|---|---|---|---|---|---|---|
Market Cap Market CapitalizationCr | 71 | 230 | ||||
Price To Earnings Price To Earnings | 7.3 | 17.5 | ||||
Price To Sales Price To Sales | 0.8 | 2.3 | ||||
Price To Book Price To Book | 1.3 | 4.2 | ||||
EV To EBITDA EV To EBITDA | 5.3 | 11.8 | ||||
GPM GPM% | 29.3 | 29.5 | 25.5 | 25.5 | ||
OPM OPM% | 7.4 | 6.7 | 19.2 | 20.7 | 16.7 | 19.9 |
NPM NPM% | 0.4 | 0.3 | 11.2 | 11.8 | 10.8 | 13.0 |
ROCE ROCE% | 12.6 | 38.1 | 20.8 | 25.5 | ||
ROE ROE% | 27.2 | 44.4 | 17.7 | 20.9 | ||
ROA ROA% | 5.4 | 17.0 | 12.6 | 15.0 | ||
| Financial Year | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Current |
|---|---|---|---|---|---|---|
Market Cap Market CapitalizationCr | 71 | 230 | ||||
Price To Earnings Price To Earnings | 7.3 | 17.5 | ||||
Price To Sales Price To Sales | 0.8 | 2.3 | ||||
Price To Book Price To Book | 1.3 | 4.2 | ||||
EV To EBITDA EV To EBITDA | 5.3 | 11.8 | ||||
GPM GPM% | 29.3 | 29.5 | 25.5 | 25.5 | ||
OPM OPM% | 7.4 | 6.7 | 19.2 | 20.7 | 16.7 | 19.9 |
NPM NPM% | 0.4 | 0.3 | 11.2 | 11.8 | 10.8 | 13.0 |
ROCE ROCE% | 12.6 | 38.1 | 20.8 | 25.5 | ||
ROE ROE% | 27.2 | 44.4 | 17.7 | 20.9 | ||
ROA ROA% | 5.4 | 17.0 | 12.6 | 15.0 | ||
| Market CapitalizationMkt CapCr | 2,722 | 1,984 | 1,812 | 230 | 149 | 128 | 123 |
| Close PriceClose₹ | 220.76 | 961.25 | 115.57 | 207.00 | 135.00 | 158.00 | 57.08 |
| IndustryIndustry | Pharma CRAMS | Pharma CRAMS | Pharma CRAMS | Pharma CRAMS | Pharma CRAMS | Pharma CRAMS | Pharma CRAMS |
| Price To EarningsPE | 30.41 | 17.54 | 17.26 | 17.34 | |||
| Price To SalesPS | 1.47 | 2.19 | 0.66 | 2.28 | 1.09 | 1.83 | 4.58 |
| RevenueRevenueCr | 1,851 | 904 | 2,756 | 101 | 137 | 70 | 27 |
| Revenue Growth TTMRev Gr TTM% | 8.9% | 19.0% | -0.1% | 22.3% | 54.7% | -1.4% | |
| PAT Growth TTMPAT Gr TTM% | -149.5% | 8.9% | -184.9% | 44.5% | -3.4% | 51.4% |
| Market CapitalizationMkt CapCr | 2,722 | 1,984 | 1,812 | 230 | 149 | 128 | 123 |
| Close PriceClose₹ | 220.76 | 961.25 | 115.57 | 207.00 | 135.00 | 158.00 | 57.08 |
| IndustryIndustry | Pharma CRAMS | Pharma CRAMS | Pharma CRAMS | Pharma CRAMS | Pharma CRAMS | Pharma CRAMS | Pharma CRAMS |
| Price To EarningsPE | 30.41 | 17.54 | 17.26 | 17.34 | |||
| Price To SalesPS | 1.47 | 2.19 | 0.66 | 2.28 | 1.09 | 1.83 | 4.58 |
| RevenueRevenueCr | 1,851 | 904 | 2,756 | 101 | 137 | 70 | 27 |
| Revenue Growth TTMRev Gr TTM% | 8.9% | 19.0% | -0.1% | 22.3% | 54.7% | -1.4% | |
| PAT Growth TTMPAT Gr TTM% | -149.5% | 8.9% | -184.9% | 44.5% | -3.4% | 51.4% |